Neurocrine Biosciences (NBIX) Share-based Compensation Growth (3y) (2013 - 2026)
Neurocrine Biosciences (NBIX) Share-based Compensation Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | 10.06% |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | 9.14% |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | 0.43% |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | -8.13% |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | -1.73% |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | -8.04% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn | 50.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.73% |
| Mar 31, 2026 | 11.76% |
| Sep 30, 2025 | -41.19% |
| Jun 30, 2025 | 50.77% |
| Mar 31, 2025 | 12.58% |
| Dec 31, 2024 | 23.09% |
| Sep 30, 2024 | 47.93% |
| Jun 30, 2024 | -40.61% |
| Mar 31, 2024 | 40.63% |
| Dec 31, 2023 | 28.54% |
| Sep 30, 2023 | -15.42% |
| Jun 30, 2023 | 71.05% |
| Mar 31, 2023 | 20.51% |
| Dec 31, 2022 | -100.70% |
| Sep 30, 2022 | 85.51% |
| Jun 30, 2022 | -59.62% |
| Mar 31, 2022 | 32.79% |
| Dec 31, 2021 | 40.86% |
| Sep 30, 2021 | -15.14% |
| Jun 30, 2021 | 56.59% |